Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of trastuzumab plus AUY922 in HER2-positive NSCLC
2011-005655-13Phase 2Completed
- Sponsor
- University of Cologne
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab and Luminespib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Cologne. Primary endpoint: Objective response rate. Started May 2012; status: completed.
02
Drugs
trastuzumabLuminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-005655-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005655-13.